Speed matters to raise molar radioactivity: Fast HPLC shortens the quality control of C-11 PET-tracers

The decision whether an in-house produced short-lived radiopharmaceutical can be applied in-vivo is based on (1) the fulfilment of all quality criteria; (2) the availability of enough radioactivity for subsequent imaging; and (3) a molar activity (MA) above the set limits to guarantee safe administration without competing occupancy of the non-radioactive compound; and (4) an activity concentration, which is high enough for the application in certain preclinical studies. Hence, time reduction can be of major importance to increase final product yields, MA and activity concentrations.
Source: Nuclear Medicine and Biology - Category: Nuclear Medicine Authors: Source Type: research